FY2028 EPS Estimates for Prothena Increased by HC Wainwright

Prothena Co. plc (NASDAQ:PRTA) – Equities research analysts at HC Wainwright raised their FY2028 earnings per share estimates for shares of Prothena in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of $3.34 for the year, up from their prior estimate of $3.26. HC Wainwright has a “Buy” rating and a $84.00 price objective on the stock. The consensus estimate for Prothena’s current full-year earnings is ($2.34) per share.

Prothena (NASDAQ:PRTA) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. The business had revenue of $0.97 million for the quarter, compared to analyst estimates of $1.22 million. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The company’s revenue for the quarter was down 98.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.38 earnings per share.

Several other analysts have also recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research report on Monday, September 30th. StockNews.com upgraded shares of Prothena from a “sell” rating to a “hold” rating in a report on Monday, August 12th. Bank of America lowered their price target on Prothena from $33.00 to $31.00 and set a “neutral” rating on the stock in a research report on Tuesday, October 1st. Royal Bank of Canada lowered their price target on Prothena from $28.00 to $24.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. Finally, Oppenheimer dropped their target price on Prothena from $66.00 to $62.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Prothena presently has an average rating of “Moderate Buy” and a consensus target price of $61.86.

Prothena Trading Down 13.0 %

Shares of NASDAQ PRTA opened at $14.01 on Friday. The business has a 50 day simple moving average of $18.19 and a 200-day simple moving average of $20.34. Prothena has a twelve month low of $14.00 and a twelve month high of $41.54. The company has a market capitalization of $753.86 million, a price-to-earnings ratio of -5.65 and a beta of 0.16.

Hedge Funds Weigh In On Prothena

Hedge funds have recently made changes to their positions in the stock. Signaturefd LLC increased its holdings in shares of Prothena by 182.1% during the second quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 863 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Prothena in the first quarter valued at $96,000. China Universal Asset Management Co. Ltd. increased its holdings in Prothena by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 4,026 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Prothena in the third quarter worth $210,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Prothena by 13.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company’s stock valued at $211,000 after acquiring an additional 1,186 shares during the last quarter. 97.08% of the stock is currently owned by institutional investors.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.